Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.05, $0.28 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $43 million versus the consensus estimate of $41.4 million.

GUIDANCE:

Anika Therapeutics sees FY 2024 revenue of $168-173 million, versus the consensus of $179.4 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.